At the 2025 WCLC, Wayshine Biopharm announced the latest data from the Phase I/II clinical study of its fourth-generation EGFR inhibitor, WSD0922-FU, for the treatment of EGFR C797S-mutant non-small cell lung cancer (NSCLC).